Figures computed from official regulatory filings — .
Analysttarget 4.5 USD (+1262%)
Ownershipinsiders 21.68% · institutions 3.68% · short 3.0% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Cosmos Health Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
67 buys211 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Siokas Grigoriostrack record | Buy | $70K | conv 33 |
| Terzis Georgios | Award | $60K | SEC |
| Siokas Grigoriostrack record | Buy | $140K | conv 44 | SEC |
| Terzis Georgios | Buy | $42K | conv 66First in 12mo | SEC |
| Siokas Grigoriostrack record | Buy | $45K | conv 33 | SEC |
| Siokas Grigoriostrack record | Buy | $160K | conv 48 | SEC |
| Demetriades Demetrios G. | Award | $5.7K | SEC |
| Terzis Georgios | Other | $490 | SEC |
| Demetriades Demetrios G. | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Terzis Georgios | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aslidis Anastasios | Award | $11.3K | SEC |
| Bhutawala Suhel | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Siokas Grigoriostrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Terzis Georgios | Award | $240.5K | Unusual size | SEC |
| Aslidis Anastasios | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Siokas Grigoriostrack record | Other | $1.4K | SEC |
| Karkantzos Theodoros Christos | Other | $15 | SEC |
| Hoidas John James | Other | $15 | SEC |
| Aslidis Anastasios | Other | $20 | SEC |
| Hoidas John James | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Karkantzos Theodoros Christos | Award | $5.7K | SEC |
| Siokas Grigoriostrack record | Other | $100 | SEC |
| Hoidas John James | Award | $5.7K | SEC |
| Siokas Grigoriostrack record | Award | $665K | SEC |
| Demetriades Demetrios G. | Other | $15 | SEC |